Mohini Mishra

About

I am Mohini Mishra, Ph.D. (thesis submitted) from the Indian Institute of Technology, BHU. My research primarily contributed to the development of innovative drug delivery methods, particularly for lung cancer. The research is focused on the evaluation of lipid and polymer-based nano-drug delivery systems for the treatment of lung cancer and dermal application.

I am deeply committed to leveraging my technical expertise to safeguard and advance innovative technologies through intellectual property law.

Employment

Employment history is unavailable.

Education

• Indian Institute of Technology BHU Ph.D.
  2019 - 2025
• Central University of Rajasthan M.Pharm
  2017 - 2019

Projects & Funding

Projects & funding information is unavailable.

Publications (18)

• Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy
  Molecular Pharmaceutics 2025 DOI: 10.1021/acs.molpharmaceut.4c00957
  +Save
• Epigallocatechin-3-gallate Synergistically Inhibits the Proliferation of Lung Cancer Cells with Gemcitabine by Induction of Apoptosis Mediated by ROS Generation
  ACS Applied Bio Materials 2024 DOI: 10.1021/acsabm.4c00958
  +Save
• Evaluation of Gemcitabine and Epigallocatechin-3-Gallate Loaded Solid Lipid Nanoparticles on Benzopyrene Induced Lung Cancer Model Via Intranasal Route: Improved Pharmacokinetics and Safety Profile
  AAPS PharmSciTech 2024 DOI: 10.1208/s12249-024-02892-w
  +Save
• Lipid-based microemulsion gel for the topical delivery of methotrexate: an optimized, rheologically acceptable formulation with conducive dermatokinetics
  Archives of Dermatological Research 2024 DOI: 10.1007/s00403-024-03140-8
  +Save
• In Vivo Cancer Microenvironment Responsive Glycan Receptor-Targeted Nanoparticles for Gemcitabine Delivery to Benzo[a]pyrene-Induced Lung Cancer Model
  AAPS PharmSciTech 2023 DOI: 10.1208/s12249-023-02714-5
  +Save
• COVID-19 Therapy
  Interaction of Coronavirus Disease 2019 with other Infectious and Systemic Diseases 2023 DOI: 10.1201/9781003324911-14
  +Save
• Dual targeting pH responsive chitosan nanoparticles for enhanced active cellular internalization of gemcitabine in non-small cell lung cancer
  International Journal of Biological Macromolecules 2023 DOI: 10.1016/j.ijbiomac.2023.126057
  +Save
• Repurposing Drugs: A New Paradigm and Hopes for Life-threatening Diseases
  Drug Repurposing Against SARS-CoV-2 2023 DOI: 10.2174/9789815123197123010004
  +Save
• Factorial Design-Based Nanocarrier Mediated Formulation of Efavirenz and Its Characterization
  Nano LIFE 2022 DOI: 10.1142/s1793984422500027
  +Save
• New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy
  Current Research in Pharmacology and Drug Discovery 2022 DOI: 10.1016/j.crphar.2022.100103
  +Save